Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
Asteroid Impact Identified as Cause of Silverpit Crater in North Sea
Scientists have likely solved a geological mystery that has puzzled researchers for over two decades. New findings suggest that the Silverpit Crater, located beneath the seabed of the North Sea, was formed...





Discussion about this post